Table 1.
Respiratory panel testing, respiratory pathogens, and total positives per target at Johns Hopkins between November 2021 and February 2022 using the extended respiratory panel (ePlex GenMark, RP2) and the Xpert Xpress SARS-CoV-2/Flu/RSV (Cepheid). RSV (respiratory syncytial virus), HCoV (coronavirus; HKU1, NL63, 229E, OC43), HMPV (human metapneumovirus), HPIV (human parainfluenza virus).
| Total Tested | November- 2021 | December- 2021 | January-2022 | February-2022 |
|---|---|---|---|---|
| ePlex (RP2) (3313) | 863 | 976 | 898 | 576 |
| Xpert Xpress SARS-CoV-2/Flu/RSV (35,809) | 7316 | 13,108 | 9582 | 5803 |
| SARS-CoV-2 (120,508) | 27,148 | 37,944 | 33,129 | 22,287 |
| Single targets | Total Positives (%) | |||
| influenza A | 53 (0.72) |
390 (2.98) |
130 (1.36) |
104 (1.79) |
| influenza B | 1 (0.01) |
1 (0.01) |
0 (0.00) |
1 (0.02) |
| RSV | 353 (4.83) |
238 (1.82) |
52 (0.54) |
26 (0.45) |
| adenovirus | 8 (0.93) |
19 (1.95) |
20 (2.23) |
19 (3.30) |
| HCoV | 5 (0.58) |
13 (1.33) |
15 (1.67) |
14 (2.43) |
| HMPV | 12 (1.39) |
19 (1.95) |
20 (2.23) |
11 (1.91) |
| enterovirus/rhinovirus | 153 (17.73) |
150 (15.37) |
41 (4.57) |
51 (8.85) |
| HPIV1 | 0 (0.00) |
0 (0.00) |
0 (0.00) |
0 (0.00) |
| HPIV2 | 12 (1.39) |
2 (0.20) |
0 (0.00) |
0 (0.00) |
| HPIV3 | 12 (1.39) |
9 (0.92) |
1 (0.11) |
1 (0.17) |
| HPIV4 | 3 (0.35) |
6 (0.61) |
1 (0.11) |
1 (0.17) |
| SARS-CoV-2 | 726 (2.67) |
7078 (18.65) |
7838 (23.66) |
838 (3.76) |
| SARS-CoV-2 (Symptomatic only) | 592 (5.70) |
6236 (25.50) |
6438 (36.70) |
533 (7.59) |
| SARS-CoV-2 by RP2 (% to total tested by RP2) | 17 (1.97) | 99 (10.14) | 124 (13.81) | 19 (3.3) |
| SARS-CoV-2 by Xpert Xpress SARS-CoV-2/Flu/RSV (% to total tested by Xpert) | 115 (1.57) | 672 (5.13) | 861 (8.99) | 100 (1.72) |